BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXL, BCTXW, BCTXZ on Nasdaq
Location
West Vancouver, British Columbia, Canada
Fiscal year end
31 July
Latest financial report
10-Q - Q3 2025 - 11 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 316% % 151%
Return On Equity -274% % -156%
Return On Assets -188% % 1.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,883,906 shares -96%
Common Stock, Shares, Outstanding 1,883,906 shares -95%
Entity Public Float $94,477,705 USD 48%
Common Stock, Value, Issued $101,739,923 USD 24%
Weighted Average Number of Shares Outstanding, Basic 1,883,906 shares 961%
Weighted Average Number of Shares Outstanding, Diluted 1,883,906 shares 961%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $24,288,980 USD 1.3%
General and Administrative Expense $6,085,934 USD 1.5%
Operating Income (Loss) $30,374,914 USD -1.3%
Nonoperating Income (Expense) $261,443 USD 177%
Net Income (Loss) Attributable to Parent $28,707,257 USD -73%
Earnings Per Share, Basic -33.87 USD/shares 56%
Earnings Per Share, Diluted -33.87 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,714,012 USD -53%
Accounts Receivable, after Allowance for Credit Loss, Current $15,233 USD 2.3%
Assets, Current $11,348,407 USD 38%
Property, Plant and Equipment, Net $273,980 USD -25%
Intangible Assets, Net (Excluding Goodwill) $180,707 USD -7.8%
Assets $13,075,050 USD 26%
Liabilities, Current $3,317,773 USD -33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $138,684 USD 0%
Retained Earnings (Accumulated Deficit) $119,953,129 USD -31%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $9,350,404 USD 152%
Liabilities and Equity $13,075,050 USD 26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,704,796 USD -11%
Net Cash Provided by (Used in) Financing Activities $11,960,252 USD
Net Cash Provided by (Used in) Investing Activities $75,000 USD 0%
Common Stock, Shares, Issued 1,883,906 shares 1445%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,779,796 USD -258%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,714,012 USD -53%
Deferred Tax Assets, Valuation Allowance $24,329,720 USD 35%
Deferred Tax Assets, Gross $28,431,010 USD 30%
Depreciation $22,839 USD 0%
Property, Plant and Equipment, Gross $456,801 USD
Deferred Tax Assets, Operating Loss Carryforwards $8,494,300 USD 53%
Unrecognized Tax Benefits $0 USD
Deferred Tax Assets, Net of Valuation Allowance $4,101,290 USD 4.9%
Share-based Payment Arrangement, Expense $392,215 USD 39%